Gaspar Requena Aspas

6PUBLICATIONS
95CO-AUTHORS
Medical infection agents (incl. prions)Gene and molecular therapyOtorhinolaryngologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 17, 2026
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Apr 22, 2026
Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

|Mar 25, 2026
Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Zofia Gross

|Feb 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.

Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard

|May 21, 2025
Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.

Curtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena

Pageof 1

Frequent Collaborators

5 joint publications

Emmanuelle Tavernier-Tardy

2 joint publications

Curtis A Lachowiez

2 joint publications

Mael Heiblig

2 joint publications

Joshua F Zeidner